Vaxart, Inc. (VXRT) stock
VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026Market cap $115.15MP/E 3.2Yield –
Vaxart shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Vaxart's shares outstanding was 242M at Jun 30, 2026. For fiscal 2025 it was 230M, up 14.0% from the year before. Over ten years it grew 22.1% a year on average. The highest annual figure on record is 230M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 230M | +14.0% |
| FY2024 | Dec 31, 2024 | 202M | +39.6% |
| FY2023 | Dec 31, 2023 | 145M | +13.4% |
| FY2022 | Dec 31, 2022 | 128M | +5.1% |
| FY2021 | Dec 31, 2021 | 121M | +37.6% |
| FY2020 | Dec 31, 2020 | 88M | +309.4% |
| FY2019 | Dec 31, 2019 | 22M | +241.5% |
| FY2018 | Dec 31, 2018 | 6M | -83.7% |
| FY2016 | Jun 30, 2016 | 39M | +9.3% |
| FY2015 | Jun 30, 2015 | 35M | +12.8% |
| FY2014 | Jun 30, 2014 | 31M | +11.1% |
| FY2013 | Jun 30, 2013 | 28M | +24.2% |
| FY2012 | Jun 30, 2012 | 23M | -55.1% |
| FY2009 | Dec 26, 2009 | 51M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | 242M | +6.0% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | 242M | +6.3% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | 236M | +3.6% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | 229M | +0.6% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | 228M | +23.6% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | 228M | +35.0% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | 228M | +60.4% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | 227M | +49.6% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | 185M | +32.3% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | 169M | +24.8% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | 142M | +7.8% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | 152M | +19.8% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | 140M | +10.4% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | 135M | +7.5% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | 132M | +4.9% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | 127M | +2.3% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | 126M | +4.6% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | 126M | +9.0% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | 125M | +14.3% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | 124M | +15.1% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | 121M | +61.9% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | 115M | +90.2% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | 110M | +575.9% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | 108M | +637.9% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | 75M | +922.8% |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | 61M | +748.6% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | 16M | +127.5% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | 15M | +104.4% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | 7M | +37.8% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | 7M | -81.5% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | 7M | -81.5% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | 7M | -81.5% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | 5M | -86.3% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | 39M | +7.1% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | 39M | +10.0% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | 39M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | 39M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | 36M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | 35M | – |
See a number that looks wrong?